Market Snapshot

BSE Sensex: 85213.36 -0.06%
BSE 500: 37232.38 0.01%
BSE 200: 11750.56 -0.02%
BSE 100: 27239.27 -0.03%
BSE MidCap: 46552.5 0.16%
BSE SmallCap: 51096.88 0.41%
BSE BANKEX: 66710.44 0.07%
BSE IT: 37118.49 0.31%
Nifty 50: 26027.3 -0.08%
Nifty 500: 23725.2 -0.00%
Nifty 200: 14461.9 -0.05%
Nifty 100: 26555.35 -0.04%
Nifty Midcap 100: 60212.8 -0.12%
Nifty Small 100: 17425.85 0.21%
Nifty IT: 38386.3 0.29%
Nifty PSU Bank: 8285.75 0.46%

News:

Newgen Software?s Saudi Arabia...
ESAF SFB gains after board OKs...
Embassy Developments Ltd leads...
Urban Company slides after sha...
Vascon Engineers gains after b...

Emcure Pharmaceuticals Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

15 Dec 2025 | 03:59 PM

1,396.60

-43.00 (-2.99%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

2.75%

Return (1Y)

Beaten BSE Healthcare by 2.95%
More Volatile

2.47%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.5%
Not so consistent

6/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

1,525

890

News & Announcements

Emcure Pharmaceuticals consolidated net profit rises 25.13% in the September 2025 quarter
34 days ago

Emcure Pharmaceuticals consolidated net profit rises 25.13% in the September 2025 quarter

11 - Nov - 2025 12:00 | 34 days ago

Net profit of Emcure Pharmaceuticals rose 25.13% to Rs 243.46 crore in the quarter ended September 2025 as against Rs 194.57 crore during the previous quarter ended September 2024. Sales rose 13.38% to Rs 2269.82 crore in the quarter ended September 2025 as against Rs 2001.98 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 2269.82 2001.98 13

OPM % 20.95 19.03 -

PBDT 446.06 370.31 20

PBT 341.42 273.41 25

NP 243.46 194.57 25

Powered by Capital Market - Live News
Novo Nordisk India partners with Emcure launch Poviztra? in India
35 days ago

Novo Nordisk India partners with Emcure launch Poviztra? in India

10 - Nov - 2025 12:00 | 35 days ago

Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra?, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.

Wegovy? (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy? experienced weight loss of over 20%.2 Poviztra? is a second brand of Wegovy?.

This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviz tra?, semaglutide injection 2.4 mg, in India.
Powered by Capital Market - Live News
Emcure Pharmaceuticals to hold board meeting
41 days ago

Emcure Pharmaceuticals to hold board meeting

04 - Nov - 2025 12:00 | 41 days ago

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.
Powered by Capital Market - Live News
Emcure Pharmaceuticals' Kadu unit clears USFDA inspection
66 days ago

Emcure Pharmaceuticals' Kadu unit clears USFDA inspection

10 - Oct - 2025 12:00 | 66 days ago

Emcure Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) had conducted surveillance inspection of Company's manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka - Lakhtar, District- Surendranagar, Gujarat - 382775, from 06 October 2025 to 10 October 2025. The inspection is concluded without any observation.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Emcure Pharmaceuticals Ltd has increased by 15.21% since past 3 Months
MF shareholding in Emcure Pharmaceuticals Ltd has increased by 53.21% since past 3 Months
FII shareholding in Emcure Pharmaceuticals Ltd has increased by 13.13% since past 1 Year
MF shareholding in Emcure Pharmaceuticals Ltd has increased by 8.49% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	2269.82	2001.98	13
OPM %	20.95	19.03	-
PBDT	446.06	370.31	20
PBT	341.42	273.41	25
NP	243.46	194.57	25

General Notifications

My Notifications

Research Notifications

Emcure Pharmaceuticals Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,396.60 -43.00 (-2.99%)

News & Announcements

Price vs Volume

Stock Trivia

Emcure Pharmaceuticals Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,396.60

-43.00 (-2.99%)